Antibody Response Against the Glomerular Basement Membrane Protein Agrin in Patients with Transplant Glomerulopathy

Chronic allograft nephropathy (CAN) of renal allografts is still the most important cause of graft loss. A subset of these patients have transplant glomerulopathy (TGP), characterized by glomerular basement membrane (GBM) duplications, but of unknown etiology. Recently, a role for the immune system in the pathogenesis of TGP has been suggested. In 11 of 16 patients with TGP and in 3 of 16 controls with CAN in the absence of TGP we demonstrate circulating antibodies reactive with GBM isolates. The presence of anti‐GBM antibodies was associated with the number of rejection episodes prior to diagnosis of TGP. Sera from the TGP patients also reacted with highly purified GBM heparan sulphate proteoglycans (HSPG). Indirect immunofluorescence with patient IgG showed a GBM‐like staining pattern and colocalization with the HSPGs perlecan and especially agrin. Using patient IgG, we affinity purified the antigen and identified it as agrin. Reactivity with agrin was found in 7 of 16 (44%) of patients with TGP and in 7 of 11 (64%) patients with anti‐GBM reactivity. In conclusion, we have identified a humoral response against the GBM‐HSPG agrin in patients with TGP, which may play a role in the pathogenesis of TGP.

[1]  F. Dekker,et al.  Immunologic risk factors and glomerular C4d deposits in chronic transplant glomerulopathy. , 2004, Kidney international.

[2]  P. Halloran,et al.  Peritubular Capillary Changes and C4d Deposits Are Associated with Transplant Glomerulopathy But Not IgA Nephropathy , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  M. Broyer,et al.  Clinical significance of allograft glomerulopathy , 1994, Pediatric Nephrology.

[4]  K. Nitta,et al.  C4d deposition in the glomeruli and peritubular capillaries associated with transplant glomerulopathy , 2003, Clinical transplantation.

[5]  Y. Sijpkens,et al.  Chronic rejection in renal transplantation , 2003 .

[6]  K. Tryggvason,et al.  Alport's syndrome, Goodpasture's syndrome, and type IV collagen. , 2003, The New England journal of medicine.

[7]  B. Hudson,et al.  Molecular characterization of the target antigens of anti-glomerular basement membrane antibody disease , 2003, Springer Seminars in Immunopathology.

[8]  Markus Exner,et al.  Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. , 2002, Journal of the American Society of Nephrology : JASN.

[9]  C. van Kooten,et al.  Antibody response against perlecan and collagen types IV and VI in chronic renal allograft rejection in the rat. , 2002, The American journal of pathology.

[10]  B. Kasiske,et al.  A thirty percent chronic decline in inverse serum creatinine is an excellent predictor of late renal allograft failure. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  W. Hörl,et al.  Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. , 2002, Journal of the American Society of Nephrology : JASN.

[12]  S. Sumitran-Holgersson,et al.  HLA-specific alloantibodies and renal graft outcome. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  R. Colvin,et al.  Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. , 2001, Journal of the American Society of Nephrology : JASN.

[14]  W. Land,et al.  Impact of humoral alloreactivity early after transplantation on the long-term survival of renal allografts. , 2001, Kidney international.

[15]  J. Sanes,et al.  Agrin isoforms with distinct amino termini: differential expression, localization, and function. , 2000 .

[16]  J. van den Born,et al.  Glomerular heparan sulfate alterations: mechanisms and relevance for proteinuria. , 2000, Kidney international.

[17]  D. Ellison,et al.  Improved graft survival after renal transplantation in the United States, 1988 to 1996. , 2000, The New England journal of medicine.

[18]  T. Meyer,et al.  Transplant glomerulopathy as a cause of late graft loss. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  S. Takemoto,et al.  Anti-HLA antibodies after solid organ transplantation. , 2000, Transplantation.

[20]  D. Leehey,et al.  Improved graft survival after renal transplantation in the United States, 1988 to 1996. , 2000, The New England journal of medicine.

[21]  R. Colvin,et al.  Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. , 1999, Journal of the American Society of Nephrology : JASN.

[22]  A. Groffen,et al.  Recent insights into the structure and functions of heparan sulfate proteoglycans in the human glomerular basement membrane. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[23]  B. Hudson,et al.  Goodpasture antigen: expression of the full-length alpha3(IV) chain of collagen IV and localization of epitopes exclusively to the noncollagenous domain. , 1999, Kidney international.

[24]  J. Wetzels,et al.  Immunohistological and ultrastructural differences between recurrent type I membranoproliferative glomerulonephritis and chronic transplant glomerulopathy. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[25]  A. Groffen,et al.  Differential Expression of Agrin in Renal Basement Membranes As Revealed by Domain-specific Antibodies* , 1998, The Journal of Biological Chemistry.

[26]  R. Iozzo.  Matrix proteoglycans: from molecular design to cellular function. , 1998, Annual review of biochemistry.

[27]  A. Groffen,et al.  Primary structure and high expression of human agrin in basement membranes of adult lung and kidney. , 1998, European journal of biochemistry.

[28]  M. Ruegg,et al.  Agrin Is a Major Heparan Sulfate Proteoglycan in the Human Glomerular Basement Membrane , 1998, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[29]  J. Fallon,et al.  Alternative splicing of agrin regulates its binding to heparin alpha-dystroglycan, and the cell surface. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[30]  K. Shu,et al.  Transplant glomerulopathy--a clinicopathological study. , 1996, Transplantation proceedings.

[31]  J. D. de Fijter,et al.  Immunoglobulin A subclass measurement in serum and saliva: sensitivity of detection of dimeric IgA2 in ELISA depends on the antibody used. , 1995, Journal of immunological methods.

[32]  L. Paul.  Chronic renal transplant loss. , 1995, Kidney international.

[33]  J. van den Born,et al.  Monoclonal antibodies against the protein core and glycosaminoglycan side chain of glomerular basement membrane heparan sulfate proteoglycan: characterization and immunohistological application in human tissues. , 1994, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[34]  M. Mihatsch,et al.  Diagnostic criteria for chronic rejection/accelerated graft atherosclerosis in heart and kidney transplants: joint proposal from the Fourth Alexis Carrel Conference on Chronic Rejection and Accelerated Arteriosclerosis in Transplanted Organs. , 1993, Transplantation proceedings.

[35]  M. Daha,et al.  A novel ELISA assay for the detection of C3 nephritic factor. , 1993, Journal of immunological methods.

[36]  J. van den Born,et al.  Distribution of GBM heparan sulfate proteoglycan core protein and side chains in human glomerular diseases. , 1993, Kidney international.

[37]  J. van den Born,et al.  A monoclonal antibody against GBM heparan sulfate induces an acute selective proteinuria in rats. , 1992, Kidney international.

[38]  J. van den Born,et al.  Production and characterization of a monoclonal antibody against human glomerular heparan sulfate. , 1991, Laboratory investigation; a journal of technical methods and pathology.

[39]  J. van den Born,et al.  Isolation and partial characterization of heparan sulphate proteoglycan from the human glomerular basement membrane. , 1989, The Biochemical journal.

[40]  M. Paulsson,et al.  Matrix-associated heparan sulfate proteoglycan: core protein-specific monoclonal antibodies decorate the pericellular matrix of connective tissue cells and the stromal side of basement membranes , 1989, The Journal of cell biology.

[41]  R. Wood.  Kidney Transplant Rejection , 1987 .

[42]  J. Stow,et al.  Antibodies to basement membrane heparan sulfate proteoglycans bind to the laminae rarae of the glomerular basement membrane (GBM) and induce subepithelial GBM thickening , 1986, The Journal of experimental medicine.

[43]  M. First,et al.  Transplant glomerulopathy: evolution of morphologically distinct changes. , 1985, Kidney international.

[44]  J. Dormont,et al.  OBSERVATIONS IN PATIENTS WITH A WELL‐TOLERATED HOMOTRANSPLANTED KIDNEY: POSSIBILITY OF A NEW SECONDARY DISEASE , 1964, Annals of the New York Academy of Sciences.